Enhanced expression of the Epstein-Barr Virus Nuclear Antigen, EBNA1, as a Target for T-cell-Based Immunotherapy for Prevention of Viral-Associated Diseases.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1005091

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Epstein-Barr virus, (EBV) is a human herpesvirus associated with a range of human cancers. EBNA1, an important EBV antigen, was thought to be “immunologically silent” however, recent studies from our laboratory show that EBNA1 is recognized by our body's defence system and these observations raise the possibility that EBNA1 may be an exploitable, immuno-therapy target for treating EBV-associated cancers.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $356,513.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Virology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antigen processing | cancer biology | immunotherapy | infectious diseases | medical virology | structure-function | tumour immunotherapy | viral infection

Related Links